Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients

Table 1 The differentially expressed miRNAs identified between gastric cancer and adjacent normal tissues

Upregulated DEMs1	P value	Downregulated DEMs	P value
hsa-miR-199a-3p/hsa-miR-199b-3p	7.10E-05	hsa-miR-652-5p	0.000135
hsa-miR-125b-5p	2.99E-05	hsa-miR-1269b	1.13E-09
hsa-miR-199a-5p	7.65E-07	hsa-miR-665	2.86E-06
hsa-miR-223-3p	7.49E-06	hsa-miR-375	0.003304
hsa-miR-196a-5p	3.22E-07	hsa-miR-4501	1.64E-06
hsa-miR-27a-3p	0.000112	hsa-miR-4279	1.94E-10
hsa-miR-23b-3p	4.71E-05	hsa-miR-943	2.46E-05
hsa-miR-21-5p	1.36E-05	hsa-miR-148a-3p	1.53E-05
hsa-miR-100-5p	0.000197	hsa-miR-1275	0.000349
hsa-miR-20a-5p	0.000102	hsa-miR-4290	8.91E-11
hsa-miR-23a-3p	5.15E-10	hsa-miR-4268	9.16E-11
hsa-miR-1	0.002694	hsa-miR-891a	7.29E-10
hsa-miR-214-3p	1.23E-08	hsa-miR-4795-3p	3.07E-05
hsa-miR-10a-5p	2.33E-05	hsa-miR-1298	3.00E-06
hsa-miR-135b-5p	1.04E-05	hsa-miR-660-3p	1.75E-08
hsa-miR-99a-5p	0.001109	hsa-miR-4661-5p	9.22E-08
hsa-miR-20b-5p	0.000365	hsa-miR-4539	2.37E-09
hsa-miR-199b-5p	0.000291	hsa-let-7d-3p	1.10E-08
hsa-miR-10b-5p	1.83E-05	hsa-miR-4636	1.94E-06
hsa-miR-27b-3p	1.95E-05
hsa-miR-126-3p	0.004079
hsa-miR-130a-3p	0.000442
hsa-miR-142-3p	0.002661
hsa-miR-4291	1.12E-09
hsa-miR-24-3p	6.14E-06
hsa-let-7a-5p	0.0059
hsa-miR-145-5p	0.00066
hsa-miR-17-5p	3.84E-05
hsa-miR-143-5p	6.07E-05
hsa-let-7f-5p	0.001364
hsa-miR-4328	0.001281
hsa-miR-4324	3.91E-05
hsa-miR-145-3p	0.000389
hsa-miR-143-3p	0.006402
hsa-miR-95	0.000106

¹Upregulated DEMs are listed according to the rank of fold changes. DEMs: Differentially expressed miRNAs.

Table 2 Clinical features of gastric cancer patients

Variables	Case, n (%)
Age at diagnosis (yr)
< 60	113 (31.3)
≥ 60	248 (68.7)
Gender
Male	241 (66.8)
Female	120 (33.2)
T stage
T1 + T2	88 (24.4)
T3 + T4	273 (75.6)
Histologic grade
G1 + G2	134 (37.1)
G3 + G4	227 (62.9)
Race
White	234 (64.8)
Asian	83 (23.0)
Black or African American	12 (3.3)
NA	32 (8.9)
Pathologic stage
I	44 (12.2)
II	117 (32.4)
III	162 (44.9)
IV	30 (8.3)
NA	8 (2.2)
Node status
N0	111 (30.7)
N1-3	249 (69.0)
NA	1 (0.3)
Metastasis
M0	325 (90.0)
M1	22 (6.1)
Mx	14 (3.9)

NA: Not available.

Table 3 Association between the three differentially expressed miRNAs and clinical features

Variables	miR-145-3p expression		P value	miR-125b-5p expression		P value	miR-99a-5p expression		P value
	Low	High		Low	High		Low	High
Age at diagnosis (yr)
< 60	51	62	0.225	42	71	0.001a	49	64	0.096
≥ 60	129	119		138	110		131	117
T stage
T1 + T2	40	48	0.342	51	37	0.081	46	42	0.603
T3 + T4	140	133		129	144		134	139
N stage
N0	58	53	0.567	57	54	0.731	57	54	0.731
N1-3	119	124		120	123		120	123
M stage
M0	163	162	0.670	165	160	0.191	164	161	0.386
M1	10	12		8	14		9	13
Histologic grade
G1 + G2	77	57	0.026a	87	47	< 0.001a	80	54	0.004a
G3 + G4	103	124		93	134		100	127
Pathologic stage
I + II	81	80	0.876	86	75	0.221	80	81	0.954
III + IV	95	97		90	102		96	96

^aP < 0.05, statistically significant.

Table 4 Univariate and multivariate Cox regression analyses of the association between the three differentially expressed miRNAs and clinical features

Variables	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age at diagnosis (≥ 60 vs < 60)	1.373 (0.948-1.988)	0.094	1.642 (1.122-2.401)	0.011a
Pathologic stage (III + IV vs I + II)	1.825 (1.332-2.499)	< 0.001a	1.252 (0.812-1.929)	0.309
T stage (T3 + T4 vs T1 + T2)	1.864 (1.197-2.902)	0.006a	1.623 (1.012-2.603)	0.044a
N stage (N1-2 vs N0)	2.005 (1.328-3.026)	0.001a	1.602 (0.935-2.744)	0.086
M stage (M1 vs M0)	1.368 (0.964-1.941)	0.080	1.313 (0.919-1.875)	0.134
Three-DEM signature (high vs low risk)	1.442 (1.018-1.988)	0.039a	1.451 (1.033-2.040)	0.032a

^aP < 0.05, statistically significant. DEMs: Differentially expressed miRNAs.